Literature DB >> 7552622

Intraaortic stop-flow infusion: pharmacokinetic feasibility study of regional chemotherapy for unresectable gastrointestinal cancers.

A M Averbach1, O A Stuart, T A Sugarbaker, A D Stephens, V Fernandez-Trigo, F Shamsa, P H Sugarbaker.   

Abstract

BACKGROUND: This study attempted to increase the exposure of gastrointestinal tract tissues to chemotherapy by prolonging the first pass of intraaortically administered drug by temporary occlusion of vascular structures.
METHODS: Bolus infusion of 14C-labeled mitomycin C (MMC) mixed with unlabeled MMC was performed in dogs. Distribution of MMC in gastrointestinal tract tissues was studied under different types of major vessel occlusion. Three dogs with intravenous infusion constituted the control group. Vascular flow was controlled in four ways for 30 min: type I--stop-flow infusion (SFI) with clamping of the abdominal aorta above the celiac and below inferior mesenteric artery; type II--with additional clamping of the inferior vena cava above the diaphragm; type III with additional clamping of the portal vein in the hepatoduodenal ligament; and type IV--with surgical exclusion of nongastrointestinal branches of the aorta in addition to type II clamping.
RESULTS: Type II and IV produced a 3-10-fold increase in exposure to MMC of major gastrointestinal tissues as compared with intravenous infusion. Area under the curve ratios with type IV were most prominent in the following tissues: stomach, pancreas, liver, and mesenteric lymph node.
CONCLUSION: Access of MMC to several gastrointestinal tissues was increased through SFI. Type IV infusion was the most effective. Tissue exposure to MMC was especially advantageous for stomach, pancreas, liver, and mesenteric lymph node.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7552622     DOI: 10.1007/bf02307065

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

Review 1.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

2.  Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy.

Authors:  L L Gunderson; H Sosin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-01       Impact factor: 7.038

Review 3.  Overview of chemotherapy for pancreatic cancer.

Authors:  S G Arbuck
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

4.  Pharmacokinetic studies of intraaortic stop-flow infusion with 14C-labeled mitomycin C.

Authors:  A M Averbach; O A Stuart; T A Sugarbaker; A D Stephens; V Fernandez-Trigo; F Shamsa; P H Sugarbaker
Journal:  J Surg Res       Date:  1995-09       Impact factor: 2.192

5.  Patterns of failure after curative resection of pancreatic carcinoma.

Authors:  J F Griffin; S R Smalley; W Jewell; J C Paradelo; R D Reymond; R E Hassanein; R G Evans
Journal:  Cancer       Date:  1990-07-01       Impact factor: 6.860

Review 6.  Therapeutic implications of tumor physiology.

Authors:  R K Jain
Journal:  Curr Opin Oncol       Date:  1991-12       Impact factor: 3.645

Review 7.  Chemotherapy in pancreatic cancer: a rational pursuit?

Authors:  J A Wils
Journal:  Anticancer Drugs       Date:  1991-02       Impact factor: 2.248

8.  A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results.

Authors:  P H Sugarbaker; F J Gianola; A Dwyer; N R Neuman
Journal:  Surgery       Date:  1987-07       Impact factor: 3.982

9.  Pharmacokinetics and tissue uptake of mitomycin C in isolated perfusion of pancreas.

Authors:  M A Arredondo; N R Thomford; B Chaudhuri; P K Chaudhuri
Journal:  J Surg Res       Date:  1989-05       Impact factor: 2.192

Review 10.  Therapy of upper gastrointestinal tract cancers.

Authors:  D Kelsen; O T Atiq
Journal:  Curr Probl Cancer       Date:  1991 Sep-Oct       Impact factor: 3.187

View more
  2 in total

1.  Hepatic preconditioning of doxorubicin in stop-flow chemotherapy: NF-kappaB/IkappaB-alpha pathway and expression of HSP72.

Authors:  Hui Lu; Zheng-Gang Zhu; Xue-Xin Yao; Ren Zhao; Chao Yan; Yi Zhang; Bing-Ya Liu; Hao-Ran Yin; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

2.  Results of regional chemotherapy using the aortic stop-flow technique in advanced pancreatic carcinoma.

Authors:  Frank Meyer; Thomas Gebauer; Reinhard Grote; Jens Martens-Lobenhoffer; Karsten Ridwelski; Hans Lippert
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.